Dr. Dennis Gross Skincare is an American clinical skincare brand founded in 2000 by board-certified dermatologist Dr. Dennis Gross and his wife Carrie Gross in New York City. Dr. Gross, who trained as a skin cancer researcher before establishing his dermatology practice on Park Avenue, created the brand to make his most effective professional-grade formulations available to a wider audience. In 2024, Shiseido, the Japanese beauty conglomerate, completed its acquisition of the brand, adding it to its portfolio of prestige skincare properties.
While the brand is known for its chemical peel pads and clinical skincare formulations, its DRx SpectraLite line of LED light therapy devices has become a standout category. The DRx SpectraLite FaceWare Pro is an FDA-cleared LED mask that combines red and blue light therapy to address both anti-aging concerns and acne in a single three-minute treatment. The device uses 162 LEDs delivering red light at 630nm to stimulate collagen production and blue light at 415nm to target acne-causing bacteria. The brand also offers the SpectraLite EyeCare Pro, a targeted LED device for the delicate eye area, and the SpectraLite BodyWare Pro for treating larger body areas.
Dr. Dennis Gross Skincare operates across the premium and high luxury segments, with LED devices priced between $159 and $435 and the broader skincare range spanning $15 to $435. The brand maintains extensive distribution through its own e-commerce platform, Sephora, Nordstrom, Bluemercury, Space NK, and Harrods, as well as professional dermatology practices. With Shiseido's backing, the brand continues to expand its global footprint while maintaining its clinical credibility and the direct involvement of Dr. Gross in product development.